Videos
Jeffrey Cleland, president and CEO, Graybug Vision, delivered an update on its two treatments for wet age-related macular degeneration (Wet AMD) and glaucoma. The company…
Read MoreEdwin Madison, PhD, chief scientific officer, Catalyst Biosciences, says the company is developing protease therapeutic agents that work via a catalytic rather than a stoichiometric…
Read MoreShelley Boyd, MD, president and CSO, Translatum Medicus Inc. (TMi), reports the company has started raising capital to initiate preclinical studies – and possibly Phase…
Read MoreIf cost was no consideration, retina specialists would first chose Eylea for their own anti-VEGF therapy, according to an American Society of Retina Specialists survey,…
Read MoreAlimera Sciences is focused on the commercialization of ILUVIEN (fluocinolone acetonide intravitreal implant) for diabetic macular edema (DME), which received FDA approval in 2014. The…
Read MoreMost ophthalmologists are aware that Aerie Pharmaceuticals is developing Rho-kinase and norepinephrine transporter inhibitors (Rhopressa, or netarsudil) for the treatment of glaucoma, and that the…
Read MoreOcular Therapeutix has built a portfolio of products around its proprietary hydrogel technology. ReSure Sealant is FDA approved for sealing clear corneal incisions following cataract…
Read MoreIntrasurgical optical coherence tomography (OCT) is “going to make a dramatic impact on our patients’ lives,” said Eric Buckland, founder and CEO of Bioptigen, which…
Read MoreTrueVision Systems’ 3D Digital Microscope Platform recently received a boost thanks to a partnership agreement with Alcon penned just before OIS@ASRS, TrueVision CEO Forrest Fleming…
Read MoreVitrectomy technology has changed little since Robert Machemer, MD, invented his 17-gauge single-port pneumatic cutter in 1972, Bausch + Lomb senior VP and chief medical…
Read MoreIn the large world of private funding in health care, ophthalmology pales in comparison with huge sectors like oncology and cardiovascular, but ophthalmology has had…
Read MoreUS financial markets had “the worst 10-day start for Wall Street in history” in January 2016, said Andrew Gitkin, managing director and head of West…
Read MoreSUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.